Immix Biopharma Yönetim

Yönetim kriter kontrolleri 3/4

Immix Biopharma CEO'su Ilya Rachman, Jan2012 tarihinde atandı, in görev süresi 12.83 yıldır. in toplam yıllık tazminatı $ 1.13M olup, şirket hissesi ve opsiyonları dahil olmak üzere 39.5% maaş ve 60.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 4.14% ine doğrudan sahiptir ve bu hisseler $ 1.82M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.7 yıl ve 3.5 yıldır.

Anahtar bilgiler

Ilya Rachman

İcra Kurulu Başkanı

US$1.1m

Toplam tazminat

CEO maaş yüzdesi	39.5%
CEO görev süresi	12.8yrs
CEO sahipliği	4.1%
Yönetim ortalama görev süresi	3.7yrs
Yönetim Kurulu ortalama görev süresi	3.5yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Ilya Rachman'un ücretlendirmesi Immix Biopharma'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$19m
Mar 31 2024	n/a	n/a	-US$18m
Dec 31 2023	US$1m	US$446k	-US$15m
Sep 30 2023	n/a	n/a	-US$14m
Jun 30 2023	n/a	n/a	-US$11m
Mar 31 2023	n/a	n/a	-US$9m
Dec 31 2022	US$2m	US$425k	-US$8m
Sep 30 2022	n/a	n/a	-US$27m
Jun 30 2022	n/a	n/a	-US$26m
Mar 31 2022	n/a	n/a	-US$25m
Dec 31 2021	US$397k	US$193k	-US$24m

Tazminat ve Piyasa: Ilya 'nin toplam tazminatı ($USD 1.13M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 653.16K ).

Tazminat ve Kazançlar: Ilya 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Ilya Rachman (51 yo)

12.8yrs

Görev süresi

US$1,129,881

Tazminat

Dr. Ilya Rachman, MD, PhD, MBA, Co-Founder, Chairman and Chief Executive Officer at Immix Biopharma, Inc since 2012. Dr. Rachman is a pioneering physician/scientist, cell biologist and among the first to f...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ilya Rachman	Co-Founder	12.8yrs	US$1.13m	4.14% $ 1.8m
Gabriel Morris	CFO & Director	3.7yrs	US$1.13m	1.04% $ 457.3k
Graham Ross	Chief Medical Officer & Head of Clinical Development	3.4yrs	US$104.42k	0% $ 0
Sean Senn	Co-Founder	no data	Veri yok	3.28% $ 1.4m
Vladimir Torchilin	Scientific Co-Founder	12.8yrs	Veri yok	3.3% $ 1.4m
Nandan Oza	Head of Chemistry	7.5yrs	Veri yok	Veri yok
David Marks	Chief Medical Officer of Cell Therapy	1.8yrs	Veri yok	Veri yok
Gerhard Bauer	Head of Cell Therapy Manufacturing	1.8yrs	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

62yo

Ortalama Yaş

Deneyimli Yönetim: IMMX 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Ilya Rachman	Co-Founder	12.8yrs	US$1.13m	4.14% $ 1.8m
Gabriel Morris	CFO & Director	3.7yrs	US$1.13m	1.04% $ 457.3k
Jane Buchan	Independent Director	3.4yrs	US$173.63k	0.082% $ 35.9k
George Sledge	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Gary Schiller	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Larry Norton	Chair of Scientific Advisory Board	no data	Veri yok	Veri yok
Jason Hsu	Independent Director	11.8yrs	US$156.38k	3.26% $ 1.4m
Magda Marquet	Independent Director	3.4yrs	US$180.64k	0.17% $ 73.7k
Helen Adams	Lead Independent Director	3.4yrs	US$429.37k	0.64% $ 279.6k
Carey Ng	Independent Director	5yrs	US$159.88k	0.073% $ 32.0k
Razelle Kurzrock	Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Galit Lahav	Member of Scientific Advisory Board	3.3yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

60yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: IMMX 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 3.5 yıldır).

Immix Biopharma Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Immix Biopharma Announces Raymond Comenzo Joins Scientific Advisory Board of Nexcella Scientific Advisory

Independent Director recently bought US$52k worth of stock

Insufficient new directors

Immix Biopharma, Inc., Annual General Meeting, Jun 11, 2024

Director recently bought US$267k worth of stock

Director recently bought US$200k worth of stock

Recent updates

Immix Biopharma Advances CAR-T NXC-201 to Expansion Cohort Dose Level in U.S. AL Amyloidosis Trial NEXICART-2

Immix Biopharma Announces Raymond Comenzo Joins Scientific Advisory Board of Nexcella Scientific Advisory

Immix Biopharma, Inc. Announces the Addition of Three Additional Clinical Trial Sites for Its U.S. Relapsed/Refractory Al Amyloidosis Clinical Trial NEXICART-2

Independent Director recently bought US$52k worth of stock

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma, Inc. Doses 1st Patient in U.S. AL Amyloidosis Trial with CAR-T NXC-201

Insufficient new directors

New major risk - Revenue and earnings growth

Immix Biopharma, Inc. Announces Positive NXC-201 Relapsed/Refractory AL Amyloidosis Clinical Data in ASGCT 2024 Latebreaking Oral Presentation

Immix Biopharma, Inc., Annual General Meeting, Jun 11, 2024

Immix Biopharma, Inc. Announces Major Comprehensive Cancer Center as Lead Site for NXC-201 Al Amyloidosis Clinical Trial

New major risk - Shareholder dilution

Immix Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $14.999999 million.

New minor risk - Market cap size

Director recently bought US$267k worth of stock

Immix Biopharma, Inc. Announces New Clinical Data from Its Phase 1b/2a NEXICART-1

Will Immix Biopharma (NASDAQ:IMMX) Spend Its Cash Wisely?

Immix Biopharma, Inc. to Host KOL Event to Discuss Its BCMA-Targeted CAR-T Cell Therapy Candidate NXC-201 for Relapsed/Refractory AL Amyloidosis

New major risk - Financial position

Immix Biopharma Presents NXC-201 Data at 65th American Society of Hematology (ASH) Annual Meeting in 9 Relapsed/Refractory AL Amyloidosis Patients

Immix Biopharma Completes 3rd NXC-201 Engineering Batch at its U.S. CAR-T Manufacturing Site

Immix Biopharma Inc. Announces 72-Patient NXC-201 Clinical Data at the IMS 20th Annual Meeting, 95% Overall Response Rate in Multiple Myeloma

Director recently bought US$200k worth of stock

Immix Biopharma, Inc Announces U.S. Food and Drug Administration Approves Orphan Drug Designation for Immix Biopharma NXC-201 as a Treatment for Multiple Myeloma

Immix Biopharma, Inc. Appoints Yekaterina Chudnovsky as Member of the Board

Immix Biopharma, Inc. Reports 2Nd Positive Interim Clinical Trial Data Readout in Relapsed/Refractory Metastatic Colorectal Cancer in Ongoing Phase 1B/2A Imx-110 Imx-110 Clinical Trial

Is Immix Biopharma (NASDAQ:IMMX) In A Good Position To Invest In Growth?

We're Not Very Worried About Immix Biopharma's (NASDAQ:IMMX) Cash Burn Rate

Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110 + BeiGene/Novartis anti-PD-1 Tislelizumab Phase 1b/2a Combination Clinical Trial in Patients with Advanced Cancer

Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Ships Tislelizumab for Patient Dosing in its Combination Clinical Trial with IMX 110 in Advanced Solid Tumors

Immix Biopharma Announces Patient Dosing in Ongoing Phase 1B/2A Imx-110 Monotherapy Clinical Trial

Immix Biopharma, Inc. Releases and Scaled-Up GMP Batches of IMX-110 for Clinical Trial Patient Dosing

High number of new directors

Immix Biopharma, Inc. Receives Institutional Review Board Approval to Enroll Pediatric Patients in Upcoming IMX-110 Clinical Trial

Immixbio Approves 4 Additional Clinical Trial Sites for Imx-110 Clinical Trials, Complementing Existing Soft Tissue Sarcoma Lead Site

Immix Biopharma (NASDAQ:IMMX) Is In A Good Position To Deliver On Growth Plans

Immix Biopharma, Inc. Completes GMP Manufacturing of Scaled-Up Batch of IMX-110 for Clinical Trials

Immix Biopharma, Inc. Announces Positive Interim Study Data Showing That After One Cycle of Treatment, Immixbio's Lead Candidate IMX-110 Produces 75% Survival Vs. 0% Survival for Trabectedin

We're Hopeful That Immix Biopharma (NASDAQ:IMMX) Will Use Its Cash Wisely

High number of new and inexperienced directors

Immix Biopharma, Inc., Annual General Meeting, Jun 08, 2022

Immix Biopharma, Inc. Initiates Good Manufacturing Practice Manufacturing of IMX-120

Immix Biopharma, Inc. Initiates IMX-110 GMP Manufacturing Scale-Up, Potentially Accelerating Clinical Trial Data

ImmixBio Announces Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data Demonstrating 100% Completion of Planned Treatment Cycles

Immix Biopharma, Inc IMX-110 Produces 50% Positive Response Rate in First-Line-Therapy-Resistant Cancer, Surpassing the Standard of Care in Mice Study

U.S. Food and Drug Administration Approves Immix Biopharma, Inc. Rare Pediatric Disease Designation for IMX-110 as a Treatment for Life-Threatening Pediatric Cancer in Children

High number of new and inexperienced directors

Immix Biopharma, Inc. has completed an IPO in the amount of $21 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri

Ortalama Görev Süresi

Ortalama Yaş